Due to the complexity of the tumor environment in vivo, the anti‐tumor effects of PRMT5/MTA‐specific inhibitors may be somewhat attenuated, and their ability to achieve suitable therapeutic effects in the clinic might require more in‐depth studies. This evidence concerns the gene PRMT5 and neoplasm.